奥司他韦在吉利德科学公司的发现和开发。

Discovery and development of oseltamivir at Gilead Sciences.

机构信息

2158Gilead Sciences Inc, Foster City, CA, USA.

出版信息

Antivir Ther. 2022 Apr;27(2):13596535211067598. doi: 10.1177/13596535211067598.

Abstract

John Martin's untimely death in March 2021 was a huge loss for us personally, Gilead Sciences, the company he built over 30 years and the scientific community concerned with antiviral therapies. We wish to honor John's legacy by retelling the discovery and history of Tamiflu and his contributions to it. Without his vision, persistence, and keen eye for opportunities, Tamiflu would not exist and Gilead's path would not have been the same. His strategic thinking around the first oral flu drug is still quite relevant today, when we are still in the SARS-CoV-2 pandemic. John explained it simply in an interview with the Science History Institute in May 2020: "…".

摘要

约翰·马丁（John Martin）于 2021 年 3 月英年早逝，这对我们个人、吉利德科学公司（Gilead Sciences）、他 30 多年来创建的公司以及关注抗病毒疗法的科学界来说都是巨大的损失。我们希望通过讲述达菲（Tamiflu）的发现和历史以及他的贡献来纪念约翰。如果没有他的远见、坚持和敏锐的机遇眼光，达菲就不会存在，吉利德的发展道路也不会是现在这样。他对第一款口服流感药物的战略思考在今天仍然非常相关，因为我们仍处于 SARS-CoV-2 大流行之中。约翰在 2020 年 5 月接受科学历史研究所采访时简单地解释说：“......”。